>>> US Gapping up

Gapping up
In reaction to earnings/guidance:
  • BSTG +22.5%, HSGX +21.2%, ANW +19.1%, GURE +17%, LEU +14.8%, M +10.9%, HIMX +8.9%, KSS +8.4%
  • SSRI +8%, EAT +6.4%, SPKE +5.7%, MIDD +5.7%, TPIC +5.2%, (also TPI Composites extends and expands its long-term agreement with Nordex to continue to supply wind blades from its existing Izmir, Turkey manufacturing facility through 2020)
  • MICT +4.9%, BABA +4.8%, CSRA +3.4%, SEED +3.2%, NVTR +2.9%, BUFF +2.3%, DTRM +1.7%, SLW +1.1%
M&A news:
  • CHK +6.3% (Chesapeake Energy exits Barnett Shale, Announces Renegotiation Of Mid-Continent Gas Gathering Agreement; co sees 2017 adjusted production growth down 2-7%)
  • RDUS +2% (vague takeover chatter out of the UK, mentioning Shire (SHPG))
  • UN +1% (announced tha it has completed the acquisition of Dollar Shave Club)
Other news:
  • KURA +49% (co reported earnings and provided update on its Phase 2 clinical trial in HRAS mutant solid tumors with 'promising' clinical activity)
  • NVGN +9.3% (announces that it has submitted an IND application to the FDA for Cantrixil (TRX-E-002-1) in ovarian cancer)
  • JWN +5.6% (in sympathy with M earnings), YHOO +3.4% (in sympathy with BABA earnings
  • WPZ +3% (Williams Partners confirms it has conditionally committed to execute a new gas gathering agreement with a new producer customer, a private company successor to Chesapeake Energy (CHK), in the Barnett Shale)
  • CLNE +1.8% (selected as a supplier to provide natural gas upgrades to facilities in Cummins Inc.'s (CMI) Distribution Business Unit)
  • WBAI +1.7% (in sympathy with BABA earnings)
  • EXAS +1.6% (announces that Health Care Service Corp. and Florida Blue recently updated their medical policies to cover Cologuard)
  • NFLX +1.1% (Director Orange Investor LP disclosed purchase totaling ~300K shares worth ~$28.3 mln)
  • BIDU +1.1% (in sympathy with BABA earnings)
  • JD +1% (in sympathy with BABA earnings)
  • LGF +0.8% (Lions Gate Entertainment Director disclosed purchase of 50K shares, worth total of ~$1.1 mln )
  • ADXS +0.8% (Phase 2 study of axalimogene filolisbac in patients with late-stage HPV-associated oropharyngeal cancer met its stage 1 primary objective),
Analyst comments:
  • OCUL +17.3% (initiated with a Mkt Outperform at JMP Securities)
  • SEAS +1.4% (upgraded to Neutral from Underperform at Credit Suisse)